Unlikely IPO candidate Kadmon made it out in a tough IPO market amid swirling criticisms of its rather infamous current and former management, namely the…

Building on the original 2013 R&D deal between Japan’s Astellas and Cytokinetics, the two have now expanded their initial collab, which will see Astellas…

Merck has shocked ALK-Abello by returning the rights to three sublingual allergy immunotherapy tablets, triggered an 18% drop in the Danish firm's share…

We can rebuild him; we have the technology--but Americans question if we should in a new survey designed to assess attitudes to modern biotechnology advances.

Kite Pharma has always been focused on engineering a patient’s own T cells to treat their cancer. But now, it’s in-licensed tech to create off-the-shelf T-cell…

Tokai had hoped that its prostate cancer candidate could best Medivation’s Xtandi, but now the microcap biotech has instead discontinued that Phase III pivotal…

Bristol-Myers Squibb is really racking up the cancer pacts as today it pens another deal for its PD-1 checkpoint inhibitor Opdivo (nivolumab)--this time to be…

AstraZeneca and partner Moderna Therapeutics are heading to the lab for the first time together with their experimental cardiometabolic drug AZD8601.